Dermatology News and Research

Latest Dermatology News and Research

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

Study shows patient-specific factors delay skin cancer treatment

Study shows patient-specific factors delay skin cancer treatment

Denial is top reason for patients to delay treatment for skin cancer

Denial is top reason for patients to delay treatment for skin cancer

Childhood asthma risk linked with prenatal paracetamol exposure depends on antioxidant genes in mother

Childhood asthma risk linked with prenatal paracetamol exposure depends on antioxidant genes in mother

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Restylane boosts people's first impression

Restylane boosts people's first impression

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Apricus receives $733,437 grants under QTDP program

Apricus receives $733,437 grants under QTDP program

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Valeant declares one-time special dividend

Valeant declares one-time special dividend

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant third quarter revenue decreases 2% to $208.3 million

Valeant's board approves $1.5 billion securities repurchase program

Valeant's board approves $1.5 billion securities repurchase program

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

Electrophysiology Innovations Congress EP Innovations 2010 to highlight treatment of atrial fibrillation

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Valeant, Kadmon enter strategic agreement for taribavirin and ribavirin

Allergan third quarter diluted loss per share increases to $2.21

Allergan third quarter diluted loss per share increases to $2.21

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.